Title for MeetingAbstracts
Alphabetical listing of titles
36 post-transfusional (P-TRF) HIV infection in a regional city hospital since 1980.
365 schoolchildren in the AIDS battle.
38 kD ISCOMS: immune responses to the 38 kD lipoglycoprotein from Mycobacterium tuberculosis.
3D COMPUTED TOMOGRAPHY TO EVALUATE LIPOATROPHY IN HIV INFECTED PATIENTS.
3D Structure-Activity Relationship (SAR) of 1-(6-Amino-3,5-difluoropyridin-2-yl)quinolones.
3D: A Tool for Improving Patient Satisfaction and Medication Safety at Discharge.
3TC + ZDV in patients (pts) with CD4 under 50/mm3: a phase II study.
3TC in HIV positive, asymptomatic or mild ARC patients.
3TC resistance is associated with better HIV suppression than 3TC sensitivity and confers little NRTI cross resistance.
3TC-related mutations and response to therapy.
3TC/ZDV +/- abacavir (ABC) reduces CSF viral load in HIV-infected children (CNA3006).
4 -ethynyl nucleoside analogs: potent inhibitors active against multi-drug-resistant HIV variants in vitro.
4 year follow-up study of the HIV infection in high risk and control groups in Martinique (F.W.I.).
4'-ETHYNYL DIDEOXYNUCLEOSIDE ANALOGUES AS POTENTIAL INHIBITORS OF MULTIDRUG-RESISTANT HIV. A COMPARISON WITH THE ACTIVE 4'-ETHYNYL 2'-DEOXYNUCLEOSIDE SERIES.
4-Amido Phenyloxazolidinone Thioamides: Antimicrobial Activity and Pharmacokinetics in Rat.
4-Aryl-2,4-dioxobutanoic Acid Inhibitors of HIV-1 Integrase and Viral Replication in Cells.
4-year follow-up of patients with chronic stable angina referred for CABG, PTCA or medical treatment: mortality, symptoms and well-being.
4-year(1992-1995) serial prevalence study on HIV, hepatitis B and C viruses and syphilis infections in Japanese female sex workers.
407 patients (pts) with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL): the experience of the GICAT (Italian Cooperative Group on AIDS and Tumors).
415 general practitioners (GP) in a regional French area facing HIV epidemy.
44 HIV-exposed newborns - clinical, virological, and immunological follow-up.
46 Near Full-Length HIV Genome Sequences from Rakai District, Uganda Show Subtype A and D Plus 30% Unique Recombinants.
48 Week Efficacy Results: Stavudine Extended-Release (XR) Formulation as Compared to Stavudine Immediate-Release (IR) Formulation.
48-WEEK RESULTS OF AN ATAZANAVIR-BASED QD REGIMEN IN PATIENTS SWITCHING FROM BID PI-BASED HAART.
49 unusual HIV-related malignant tumors.
5 cases of severe strongyloidiasis in HIV infected patients in one AIDS care center in Guadeloupe FWI.
5 Day- versus 10 Day- Ofloxacin (OFL) Treatment in Complicated Lower Urinary Tract Infections (LUTI) in Women (W).
5 FU and clindamycin for treatment of cerebral toxoplasmosis.
5 years of reproductive assistance with ivfet in HIV discordant couples.
5'- and 3'- phosphate-like dideoxynucleosides as potential anti-HIV agents.